Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses patient-reported outcomes following autologous stem cell transplantation in multiple myeloma.
Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses patient-reported outcomes following autologous stem cell transplantation (ASCT) in multiple myeloma.
The study looked at patient-reported outcomes, financial toxicity, and cognitive function in patients who undergo autologous stem cell transplant. It is a pilot study with the purpose of obtaining information on feasibility, so that researchers can receive more grant to study a larger group of patients, says Biran.
Twenty-two patients completed pre- and post-ASCT assessments. Median age was 66. From pre- to 6-months post-ASCT, patients reported a reduction in anxiety, depression, fatigue, and pain interference. The study also reported a higher incidence of satisfaction with participation in social roles and physical function.
Biran states that approximately 75 patients have enrolled on the study to date. A preliminary analysis showed that there was also an improvement in financial stress, neuropathy, mobility, and overall cognitive function. This was based on common terminology criteria for adverse events for patients who have undergone the operation.